Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
- To determine and compare the pharmacokinetics (PK) of a single dose of 25 mg Androxal in
overweight male subjects with hepatic impairment and in volunteers with normal hepatic
function.
- To compare the safety profile of a single dose of 25 mg Androxal in overweight male
subjects with hepatic impairment and in volunteers with normal hepatic function.